0.74
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire
Spero Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc. - MarketScreener
Virtu Financial LLC Makes New $47,000 Investment in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate - Yahoo Finance
Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast - Investing.com India
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: - GuruFocus
Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast By Investing.com - Investing.com South Africa
Spero Therapeutics earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Spero Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq
Spero Q4 Earnings: $68.6M Loss, Pipeline Setbacks, and New Interim CEO Named - Stock Titan
A Glimpse of Spero Therapeutics's Earnings Potential - Benzinga
Spero Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Spero Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
Spero Therapeutics Q4 Earnings: Rare Disease Pipeline and Financial Results Coming March 27 - StockTitan
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - The AM Reporter
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges - Investing.com Australia
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges By Investing.com - Investing.com South Africa
Spero Therapeutics (SPRO) Projected to Post Earnings on Wednesday - The AM Reporter
Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN
Spero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Spero Therapeutics faces Nasdaq delisting over share price - Investing.com India
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire
UPDATESpero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Marjorie Taylor Greene Is Betting Big on Palantir Stock. Should You? - The Globe and Mail
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Rare Disease Biotech Spero Therapeutics Takes Stage at Major TD Cowen Healthcare Conference - StockTitan
Can Spero Therapeutics' Rare Disease Pipeline Impress Investors at Major Healthcare Conference? - StockTitan
Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN
Spero therapeutics CFO sells $16,137 in stock By Investing.com - Investing.com Nigeria
Spero Therapeutics Inc (SPRO)’s results reveal risk - US Post News
Spero therapeutics director Ankit Mahadevia sells $53,990 in stock By Investing.com - Investing.com Australia
Spero Therapeutics CEO sells shares worth $121,159 - MSN
자본화:
|
볼륨(24시간):